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Objectives. The aim of the study was to assess self-reported medication adherence measure in patients selected during a
health education and health promotion focused event held in the Campania region. The study also assessed sociodemographic
determinants of adherence.Methods. An interviewer assisted survey was conducted to assess adherence using the Italian version of
the 8-itemMoriskyMedicationAdherence Scale (MMAS-8). Participants older than 18 years were interviewed by pharmacists while
waiting for free-medical checkup.Results. A total of 312 participantswere interviewed during theHealthCampus event. A total of 187
(59.9%) had low adherence to medications. Pearson’s bivariate correlation showed positive association between the MMAS-8 score
and gender, educational level and smoking (𝑃 < 0.05). Amultivariable analysis showed that the level of education and smokingwere
independent predictors of adherence. Individuals with an average level of education (odds ratio (OR), 2.21, 95% confidence interval
(CI), 1.08–4.52) and nonsmoker (odds ratio (OR) 1.87, 95% confidence interval (CI), 1.04–3.35) were found to be more adherent
to medication than those with a lower level of education and smoking. Conclusion. The analysis showed very low prescription
adherence levels in the interviewed population. The level of education was a relevant predictor associated with that result.
1. Introduction
Medication adherence is a growing concern to healthcare
systems as nonadherence to pharmacotherapy has been
associated with adverse outcomes and higher costs of care.
Medication nonadherence is likely to grow as the pop-
ulation ages and as patients need to take more medications
to treat chronic conditions. Several studies highlighted that
the levels of adherence to treatment in patients with chronic
diseases are inadequate showing rates that do not exceed
50%. Adherence and persistence to drug treatment represent
the key factors necessary to gain a significant reduction in
morbidity and mortality and to optimize the use of financial
resources, but these aspects are widely underestimated in
clinical practice and by patients [1–5]. The World Health
Organization (WHO) estimates that the cost of nonadher-
ence to drug therapy amounts to 125 million euros per year
in Europe [6].
The approaches used to assess medication adherence
include direct or indirect methods. Indirect methods include
patient interviews, pill counts, refill records, and measure-
ment of health outcomes. However, the most practical
approach to apply in clinical practice is patient self-report.
The advantages of assessing medication adherence by self-
report included simplicity, speed, and viability of use [7].The
MoriskyMedicationAdherence Scale (MMAS-8) is one of the
most commonly used self-reporting methods [8, 9].
In addition, theMMAS-8 provides information onbehav-
iors associated with low adherence that may be unintentional
(e.g., forgetfulness) or intentional (e.g., stopped taking
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medication(s) without telling the doctor, because they felt
worsewhen they took it). Identification of these behaviors can
facilitate tailoring of interventions to specific patient issues
and is strongly related to concordance [7, 10].
Currently there are many studies evaluating the degree of
adherence to treatment in patients with specific diseases [7,
11–13], while there seems to be a lack in the literature related
to adherence to treatment in the general population.
The purpose of the current analysis was to evaluate
adherence to medication in the general population during a
prevention-related event held in Campania region (Southern
Italy). The interview was carried out by administering the
Italian version MMAS-8 questionnaire.
2. Materials and Methods
2.1. Setting. The prevention-related event was organized by
the Health Campus, a nonprofit organization. It was estab-
lished to carry out a continuous activity of dissemination and
promotion of prevention through specific clinical screening
and educational initiatives. The study is part of a larger
activity that started in 2010 to assess the health status of the
general population of the Campania Region, by providing
free consultation, visits, and diagnostics for people coming
to the outdoor hospital held in different public squares of
Campania region during popular events [14].
The Health Campus focuses its energy and resources
primarily on two major objectives: first, to provide specialist
visits for disease prevention and early detection of risks
to the health of Campania citizens; second, to promote
dissemination of a culture of prevention that encourages a
change in lifestyle for healthy living.
The Health Campus events periodically set up a disease
prevention “Field Clinic,” where early diagnosis tests are
offered to the general public free of charge. Thus the public
is encouraged to undergo specialist examinations and is
informed about health risks and good practice habits to adopt
for early diagnosis and screening.
The Health Campus is typically set up during large,
popular events or at the request of public and/or private
organizations.
2.2. Study Design. A cross sectional assisted interview survey
was conducted by pharmacists on a population group selected
during the Health Campus event held in Naples in April 2013
during the America’s Cup.
People who were attending the event and were interested
to undergo clinical evaluation and/or to take the opportunity
of the available screening services, upon arrival, were selected
as eligible if they were 18 years or older and taking at least
one medication for at least one chronic condition. While
waiting to receive a medical checkup, they were invited to the
assessment ofmedication adherence andwere interviewed by
pharmacists. All participants provided their written informed
consent to the study that was conducted in line with the
Helsinki declaration for human studies.
The information collected included demographic data
(i.e., age and gender), level of education (referred to Italian
education system), smoking habit, number of drugs taken,
and type of chronic disease present such as hypertension,
diabetes, heart failure, COPD, renal failure, and osteoporosis.
Self-reported adherence was assessed using the Italian val-
idated version of the Morisky Medication Adherence Scale
(MMAS-8) [15]. Use of the MMAS is protected by US
copyright laws. Permission for use is required. This scale
has been validated and used in many languages [12, 15,
16]. It consists of eight items that address specific behavior
regarding medication assumption and both intentional and
unintentional adherence (questionnaire used for interview
is reported as Supplementary Material available online at
http://dx.doi.org/10.1155/2015/682503, Table S1).
Scores on the Morisky Medication Adherence Scale can
range from 0 to 8, scores < 6 reflecting low adherence, scores
≥ 6< 8 reflectingmediumadherence, and scores = 8 reflecting
high adherence [17].
In this study, none of the interviewed participants
reported high adherence on the Morisky scale, so the depen-
dent variable of patient adherence was dichotomized into 2
groups: low adherence (scores< 6) versusmedium adherence
(scores ≥ 6) [18].
TheMMASprovides information on behaviors associated
with low adherence that may be unintentional (e.g., forget-
fulness) or intentional (e.g., stopped taking medication(s)
without telling the doctor, because they felt worse when
they took it) [7]. The MMAS-8 is divided into 4 items
that assess intentional nonadherence and 4 items that assess
unintentional nonadherence. We divided participants with
low adherence into two categories: intentional nonadherent
when majority of answers provided indicate a behavior that
is not related to forgetfulness and unintentional nonadherent
when majority of answers provided indicate a behavior that
is related to forgetfulness.
2.3. Statistical Analyses. Baseline characteristics of the study
population were analyzed using descriptive statistics and
their degree of adherence, chi square test, and Student’s t-test
were used where appropriate. Pearson’s correlation was used
to assess bivariate association between adherence score and
participant characteristic.
Additionally, associations between adherence and covari-
ates were evaluated after accounting for other variables
and predictors using logistic regression. The initial model
included gender, smoking, and educational level. Factors
were then sequentially eliminated from the multivariate
model until only factors significant at the level of P < 0.05
remained in the final model. All analyses were performed
using SPSS software version 17.1 for Windows (SPSS Inc.,
Chicago, IL, USA).
3. Results
312 patients were interviewed during the Health Campus
event. The mean age was 61.8 (SD ±11.1) years. 57.4% of
participants were women.
The characteristics of the analyzed population and the
results of univariate association between low adherence on
the Morisky scale and patient-reported factors are reported
in Table 1.
Journal of Aging Research 3
Table 1: Univariate association between low adherence on the Morisky scale and patient-reported factors.
Low adherence Medium adherence Total
𝑃 value
𝑁 = 187 (59.9%) 𝑁 = 125 (40.1%) 𝑁 = 312 (100.0%)
Age group 0.58
Mean (±SD) 62.0 (11.4) 61.7 (10.8) 61.8 (11.1)
18–60 75 (58.1) 54 (41.9) 129 (100.0)
≥60 112 (61.2) 71 (38.8) 183 (100.0)
Gender 0.03
Male 89 (66.9) 44 (33.1) 133 (100.0)
Female 98 (54.7) 81 (45.3) 179 (100.0)
Educational level 0.01
Primary school graduation 34 (68.0) 16 (32.0) 50 (100.0)
Secondary school graduation 65 (69.9) 28 (30.1) 93 (100.0)
High school graduation 55 (50.0) 55 (50.0) 110 (100.0)
Degree graduation 33 (55.9) 26 (44.1) 59 (100.0)
Number of medications 0.62
Mean (±SD) 2.33 (1.6) 2.15 (1.5) 2.26 (1.58)
1 77 (56.6) 59 (43.4) 136 (100.0)
2-3 71 (60.7) 46 (39.3) 117 (100.0)
4-5 21 (67.7) 10 (32.3) 31 (100.0)
≥6 18 (64.3) 10 (35.7) 28 (100.0)
Smoking 0.03
No 136 (56.7) 104 (43.3) 240 (100.0)
Yes 51 (70.8) 21 (29.2) 72 (100.0)
Number of diseases 0.08
Mean (±SD) 1.58 (0.87) 1.46 (0.64) 1.53 (0.78)
1 111 (59.4) 76 (40.6) 187 (100.0)
2 52 (55.9) 41 (44.1) 93 (100.0)
≥3 24 (75) 8 (25) 32 (100.0)
Heart failure 0.58
No 171 (60.4) 112 (39.6) 283 (100.0)
Yes 16 (55.2) 13 (44.8) 29 (100.0)
COPD 0.35
No 183 (59.6) 124 (40.4) 307 (100.0)
Yes 4 (80.0) 1 (20.0) 5 (100.0)
Gastritis 0.42
No 172 (59.3) 118 (40.7) 290 (100.0)
Yes 15 (68.2) 7 (31.8) 22 (100.0)
Renal failure 0.68
No 185 (60.1) 123 (39.9) 308 (100.0)
Yes 2 (50.0) 2 (50.0) 4 (100.0)
Osteoporosis 0.15
No 168 (58.7) 118 (41.3) 286 (100.0)
Yes 19 (73.1) 7 (26.9) 26 (100.0)
Diabetes mellitus 0.51
No 163 (59.3) 112 (40.7) 275 (100.0)
Yes 24 (64.9) 13 (35.1) 37 (100.0)
Hypertension 0.76
No 87 (60.8) 56 (39.2) 143 (100.0)
Yes 100 (59.2) 69 (40.8) 169 (100.0)
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18.9% of patients have a degree graduation, 35.3% of
patients had high school graduation whereas 29.8% of
patients attended secondary school graduation, and 16.0%
finished the primary schools.
A total of 40.1% of patients had 2 or more diseases. More
specifically, patients with hypertension were 169 (54.2%); 37
(11.9%) had type II diabetes; 29 (9.3%) had heart failure;
26 (8.3%) had osteoporosis; 22 (7.1%) had gastritis; 5 (1.6%)
had COPD; and 4 (1.3%) had renal failure. A total of 37.5%
of patients took from 2 to 3 drugs and 59.9% of patients
have at least one disease. A total of 76.9% of patients were
nonsmoking.
In the overall population, 59.9% of participants demon-
strated low adherence and 40.1%mediumadherence.Nobody
showed high adherence. The mean score for the medication
adherence scale was 4.95 (±1.52). Table 1 shows the charac-
teristics of the population and the significant results (P <
0.05) of the univariate analyses examining the associations
between scores on the Morisky scale and patient-reported
factors.
Considering the frequency distribution of the MMAS-8
items, 42.6% of patients answered that they forgot to take
their medicines, 47.1% of patients had problems taking their
medicines in the last two weeks, 21.8% of patients have
stopped taking their medicines without telling their doctor,
55.4% of patients stated that when they travel they forgot
to bring along their medication, 20.2% of patients stated
that when they feel like their condition is under control,
they stop taking their medication, and 18.3% of patients felt
hassled about sticking to their treatment plan. In conclusion,
19.9% of patients have difficulty remembering to take all their
medications.
A total of 60.9% of nonadherent participants were inten-
tional, 13.4%of nonadherent subjects were unintentional, and
25.7% of nonadherent participants did not fall within either
category.
The number of medications prescribed, age, and number
of diseases are not significant.
However, educational level, smoking habit, and gender
were statistically significant (P = 0.01; 0.03; 0.03, resp.)
(Table 1).
Univariate analysis showed that males have a higher risk
of being low adherent than women (odds ratio (OR) 1.67, 95%
confidence interval (CI), 1.05–2.66); the risk of being nonad-
herent to treatment for smokers is about double compared to
nonsmokers (odds ratio (OR) 0.54, 95% confidence interval
(CI) 0.30–0.95).
Only 2 factors remained as significant independent pre-
dictors of high adherence after logistic regression adjustment:
level of education (P = 0.03) and smoking habit (P = 0.03)
(Table 2).
People with high school graduation (odds ratio (OR),
2.21, 95% confidence interval (CI), 1.08–4.52) and nonsmok-
ers (odds ratio (OR) 1.87, 95% confidence interval (CI), 1.04–
3.35) are more adherent to treatment than those with lower
education and smokers (Table 2).
Table 2: Association between adherence score with educational
level and other significant variables in the regression analysis.
Variables Odds ratio IC 95% 𝑃 value
Gender
Female Reference
Male 0.65 0.39–1.06 0.08
Smoker Reference
Nonsmoker 1.87 1.04–3.35 0.03
Educational level
Primary school graduation Reference
Secondary school graduation 1.01 0.47–2.17 0.98
High school graduation 2.21 1.08–4.52 0.03
Degree graduation 1.63 0.74–3.62 0.23
4. Discussion
To the best of our knowledge, this is the first survey about
adherence to medication that was carried out during a pre-
vention event, among a population selected at the community
level.
Previous studies on adherence have mostly been
restricted to specific clinical populations, a specific disease,
and/or a single treatment and the relevance of the outcomes
to prescription drug users in general has been unclear
[19]. Patient compliance to drug therapy is one of the
most relevant issues in clinical practice as the success of
a therapeutic intervention depends on the actual patient
adherence to therapy. The noncompliance to treatment has
direct consequences such as the distortion of the effectiveness
of the treatment [20]. Furthermore, several observational
studies raised many concerns about undertreatment in
current clinical practice, because it leads to an increase in the
number of hospitalizations and consequently an increase of
the cost for the health system [21].
In industrialized countries, adherence to treatment by
patients with chronic diseases is about 50% [22]. Our results
are in line, showing 59.9% of low adherence to medications.
The main causes of poor adherence are the lack of moti-
vation of the patients as well as low average education level,
limited awareness about health, and the lack of perception of
risk arising from treatment discontinuation [11].This is in line
with our results that showed that low level of education is a
predictor of low adherence.
Moreover different studies indicate that 30% of the
interviewed participants claim forgetfulness as the reason for
their nonadherence, thus making it a prominent reason for
nonadherence [23].
Using the MMAS-8, we were able to identify intentional
and unintentional behaviors that cause low adherence [7].
About 42.6% of respondents say they do not take their
medication regularly due to forgetfulness and 21.8% stop
their treatment without speaking to their doctor. Intentional
nonadherence indicates a lack of understanding and mis-
conceptions regarding the chronicity of a health condition.
This behavior can be related to lack of concordance, intended
as the fact that the “prescriber and patient should come
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to an agreement about the regimen that the patient will
take” [10]. Taking medications continuously and according
to the instructions of the physician is an important aspect
of drug treatment. This aspect, however, does not seem to be
considered by the patients: our analysis showed that no more
than 40.1% of patients have a medium level of adherence.
The interview was carried out by pharmacists. Several
studies showed that interventions by pharmacists, often as
a part of the care team, jointly with clinicians, have been
found to be effective in improving medication adherence
[24, 25]. However in Italy pharmacists are not sufficiently
involved in adherence-related activities, despite the fact that
pharmacists are the last point of contact with the patient
before beginning the use of the medications [26]. Strategies
should be formulated to achieve greater involvement of
pharmacists in promoting adherence [27]. For this reason
we chose to involve the pharmacist in the administration
of the questionnaire as a way to improve awareness about
adherence-related issues among pharmacists as well.
The European Innovation Partnership A1 Action Group
onActive andHealthyAgeing, in 2012, has implemented joint
initiatives between various European countries to improve
the quality of the prescription and adherence to treatment
[28]. Many intervention strategies that are currently being
discussed among partners are aimed to promote coordinated
and multidisciplinary intervention by involving all major
stakeholders (general practitioners and specialists, pharma-
cists, nurses, family, health authorities, and pharmaceutical
industry). The present initiative is part of the strategy carried
out by the EIP-AHA A1 Action Group and provides pre-
liminary data that might be useful for the further focused
interventions.
4.1. Limitations of the Study. This study has some obvious
limitations. Participation in this study was voluntary and, as
a result, there may have been a selection bias. Population has
not been selected on the basis of specific diseases or according
to the number of medications prescribed. Nevertheless we
assume that to be a minor limitation as the study was
not aimed to assess adherence in specific conditions. Our
results give a first overview about level of adherence and
predictive factors. A larger population could provide more
robust results. The assessment of adherence in our study was
based on self-reporting. Questionnaires are a self-reporting
tool that is relatively simple and economical to use, but it
could overestimate the rate of medication adherence [29, 30].
5. Conclusion
In conclusion, we provided information about adherence
levels in a population selected among participants to a
prevention-related event.The analysis showed that adherence
levels were mostly low. We found that a factor that could be
associated with low levels of adherence was level of educa-
tion which in turn is related to inadequate health literacy.
Initiatives to raise awareness of the issue are needed as well
as dissemination of the fundamental principles underlying
control strategies of nonadherence to therapy. Performing
such initiatives requires a collective, joint effort that involves
different categories of stakeholders, from patient to health
care providers and policymakers, whose rolemay be different
depending upon the kind of initiative and health system
organization.
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